- Home
- SEM vs SCLXW Comparison
SEM vs SCLXW Comparison
Compare SEM & SCLXW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEM
- SCLXW
- Stock Information
- Founded
- SEM 1996
- SCLXW N/A
- Country
- SEM United States
- SCLXW United States
- Employees
- SEM N/A
- SCLXW 117
- Industry
- SEM Hospital/Nursing Management
- SCLXW Biotechnology: Pharmaceutical Preparations
- Sector
- SEM Health Care
- SCLXW Health Care
- Exchange
- SEM Nasdaq
- SCLXW Nasdaq
- Market Cap
- SEM N/A
- SCLXW N/A
- IPO Year
- SEM 2009
- SCLXW N/A
- Fundamental
- Price
- SEM $16.68
- SCLXW $0.10
- Analyst Decision
- SEM Buy
- SCLXW
- Analyst Count
- SEM 4
- SCLXW 0
- Target Price
- SEM $28.67
- SCLXW N/A
- AVG Volume (30 Days)
- SEM 913.1K
- SCLXW 4.0K
- Earning Date
- SEM 05-01-2025
- SCLXW 03-07-2025
- Dividend Yield
- SEM 2.29%
- SCLXW N/A
- EPS Growth
- SEM N/A
- SCLXW N/A
- EPS
- SEM 1.70
- SCLXW N/A
- Revenue
- SEM $5,187,105,000.00
- SCLXW $55,152,000.00
- Revenue This Year
- SEM $6.57
- SCLXW N/A
- Revenue Next Year
- SEM $5.93
- SCLXW N/A
- P/E Ratio
- SEM $45.69
- SCLXW N/A
- Revenue Growth
- SEM 7.48
- SCLXW 22.02
- 52 Week Low
- SEM $14.14
- SCLXW $0.18
- 52 Week High
- SEM $22.08
- SCLXW $0.18
- Technical
- Relative Strength Index (RSI)
- SEM 40.29
- SCLXW N/A
- Support Level
- SEM $16.81
- SCLXW N/A
- Resistance Level
- SEM $17.23
- SCLXW N/A
- Average True Range (ATR)
- SEM 0.41
- SCLXW 0.00
- MACD
- SEM 0.04
- SCLXW 0.00
- Stochastic Oscillator
- SEM 37.70
- SCLXW 0.00
About SCLXW Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.